3 Minutes
Imagine cutting more than a third of childhood typhoid cases in a single public-health sweep. That’s the scale suggested by research from India: routine vaccination in urban areas could prevent up to 36 percent of typhoid infections and related deaths among children. Short, sharp, and not hypothetical.
Vaccines are already shifting the landscape. Pakistan became the first country to roll out routine immunization against typhoid, and a handful of others are following or weighing the move. The Centers for Disease Control and Prevention notes that, by April 2025, the World Health Organization had prequalified four typhoid conjugate vaccines—tools now being introduced into childhood schedules across regions where typhoid is endemic.
Why this matters now
Antibiotic resistance is no longer tomorrow’s problem. It kills more people annually than some familiar infectious diseases, and resistant typhoid strains make treatment harder, costlier, and slower. Vaccination changes the calculus: prevent infections in the first place and the pressure that drives resistance eases. In short, vaccines are one of the few scalable, proven defenses we have against a future where common bacterial infections could again become deadly.
The evidence is building. A study published in The Lancet Microbe examined urban immunization scenarios and found substantial reductions in cases and fatalities when children received typhoid conjugate vaccines. Real-world rollout in countries like Pakistan offers early lessons about logistics, coverage gaps, and community engagement—lessons other nations can adapt rather than reinvent.
“Where vaccines reach children, we see immediate public-health returns,” says Dr. Anita Rao, an infectious-disease epidemiologist involved in regional vaccine rollouts. “But supply, political will, and funding determine whether those returns scale.” Her point is simple: the science is clear; implementation is the bottleneck.
Investing in new antibiotics remains essential. So does expanding vaccine access, strengthening surveillance for resistant strains, and supporting health systems that deliver routine childhood immunizations. The pieces fit together; the question is whether governments and global health partners will assemble them before resistance tightens its grip.
We don’t have time to waste.
Source: sciencealert
Leave a Comment